Scarica l'app Stockscreener
0.3001
15.38%
0.04
Dopo l'orario di chiusura:
.29
-0.0101
-3.37%
Precedente Chiudi:
$0.2601
Aprire:
$0.2504
Volume 24 ore:
8.74M
Relative Volume:
1.36
Capitalizzazione di mercato:
$124.32M
Reddito:
$39.55M
Utile/perdita netta:
$-122.93M
Rapporto P/E:
-0.6785
EPS:
-0.4423
Flusso di cassa netto:
$-97.31M
1 W Prestazione:
-12.79%
1M Prestazione:
-30.19%
6M Prestazione:
-57.13%
1 anno Prestazione:
-54.06%
Intervallo 1D:
$0.2311
$0.313
Intervallo di 1 settimana:
$0.205
$0.3505
Portata 52W:
$0.205
$0.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Compare SGMO vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.3001 | 124.32M | 39.55M | -122.93M | -97.31M | -0.4423 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Sangamo (NASDAQ: SGMO) awards 225,000 stock options to accounting chief - Stock Titan
Sangamo (SGMO) CEO Sandy Macrae receives 2.5M stock option grant at $0.2601 - Stock Titan
Sangamo (NASDAQ: SGMO) CLO awarded 800,000 options at $0.2601 - Stock Titan
Equities Analysts Issue Forecasts for SGMO FY2028 Earnings - MarketBeat
Sangamo Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SGMO) 2026-04-02 - Seeking Alpha
SGMO News | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty - tipranks.com
RBC Capital Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sangamo: Q4 Earnings Snapshot - theheraldreview.com
Sangamo Reports Pipeline Progress And Wider FY25 Loss, Stock Down 17% Overnight - RTTNews
Sangamo Therapeutics (SGMO) Q4 Loss Highlights Deep TTM Deficit Challenging Bullish Profitability Hopes - Sahm
Sangamo Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Sangamo Therapeutics Q4 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates By Investing.com - Investing.com Australia
Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks - MSN
SGMO Faces Uncertainty Without Additional Funding - GuruFocus
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - Moomoo
Sangamo (SGMO) Reports Robust Revenue Growth and Pipeline Progre - GuruFocus
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS - marketbeat.com
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates - Investing.com
Sangamo Therapeutics Q4 Loss Is Unchanged, Revenue Climbs - Moomoo
Sangamo Therapeutics earnings missed by $0.10, revenue fell short of estimates - ca.investing.com
Q4 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 - TradingView
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - Yahoo Finance
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Sangamo Therapeutics, Inc. Trade Ideas — LSX:936386 - tradingview.com
Sangamo Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Gains Report: Is Sangamo Therapeutics Inc a strong growth stockEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Sangamo Therapeutics Inc (SGMO) - Stock Titan
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - The Manila Times
Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight - Meyka
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
EPS Watch: Does Sangamo Therapeutics Inc have consistent dividend growth2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
Sangamo seeks accelerated US approval of gene therapy for Fabry - Fabry Disease News
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Sangamo Biosciences (SGMO) and Protalix (PLX) - The Globe and Mail
Sangamo Therapeutics (SGMO) shares stabilize amid recent key pipeline update - MSN
Fabry Disease Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Sangamo (SGMO) Advances FDA Submission for Gene Therapy Approval - GuruFocus
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
One-time Fabry gene therapy from Sangamo moves toward FDA accelerated approval - Stock Titan
Sangamo Therapeutics (SGMO) to Release Earnings on Monday - marketbeat.com
SGMO PE Ratio & Valuation, Is SGMO Overvalued - Intellectia AI
Day Trade: Is Sangamo Therapeutics Inc. (GBY) stock among top earnings playsTrade Volume Summary & Technical Pattern Alert System - Naître et grandir
Risk Report: Does Sangamo Therapeutics Inc have consistent dividend growth - baoquankhu1.vn
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
Merger Talk: Does Sangamo Therapeutics Inc have consistent dividend growth2025 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
SGMO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):